Lori Kunkel, M.D.
Lori Anne Kunkel, M.D. has more than two decades of experience in oncology and immunology drug development and commercialization. Dr. Kunkel presently serves on the Board of Directors of Loxo Oncology, Inc., Curis, Inc., Tocagen Inc. and Maverick Therapeutics Inc. She was previously the acting Chief Medical Officer at Loxo and she served as Chief Medical Officer at Pharmacyclics, Inc. (acquired by AbbVie) and Proteolix, Inc. (acquired by Onyx Pharmaceuticals, Inc.), contributing to the approvals of cancer therapeutics IMBRUVICA® and KYPROLIS®, respectively. She has advised multiple clients including Chiron Corporation (acquired by Novartis), Genentech/Roche, Salmedics (acquired by Celgene Corporation), Stemcentrx, Inc. (acquired by AbbVie), Atreca, Inc. and Verastem, Inc.
Dr. Kunkel served as a faculty member in the Division of Hematology/Oncology at University of California, Los Angeles. Dr. Kunkel obtained a medical degree from University of Southern California and a bachelor’s degree in biology from University of California, San Diego. She is board certified in internal medicine and held board certifications in hematology and oncology.
Patrick Baeuerle, Ph.D
Patrick Baeuerle, Ph.D., joined MPM in 2015, and has since co-founded MPM oncology start-ups: Harpoon Therapeutics, Inc., TCR² Therapeutics, iOmx Therapeutics AG, Maverick Therapeutics, Inc. and Cullinan Pharmaceuticals LLC. Previously, he was responsible for the development of BiTE antibody Blincyto®, which was approved in 2014 within three months of submission by the U.S. FDA for the treatment of relapsed/refractory acute lymphoblastic leukemia. He also spearheaded the BiTE technology, the industry’s leading T-cell engaging bispecific antibody platform.
Prior to joining MPM, Dr. Baeuerle served as Vice President, Research, and General Manager of Amgen Research Munich GmbH, where he oversaw translational sciences of BiTE antibodies. From 1998 to 2012, he served as Chief Scientific Officer for Micromet, Inc., and earlier headed small molecule drug discovery at Tularik, Inc., a publicly traded biotechnology company also acquired by Amgen (AMGN). From 1996-1998, he served as Professor and Chairman of Biochemistry and Molecular Biochemistry at the Medical Faculty of Freiburg University, Germany, where he did groundbreaking research on transcription factor NF-kappaB.
Dr. Baeuerle has published more 238 PubMed-listed papers that have been cited more than 64,000 times to date. He has a Hirsh index of 119 and was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990 to 1997). He holds a Ph.D. in biology from the University of Munich, and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute at the Massachusetts Institute of Technology. He is also an Honorary Professor of Immunology of the Medical Faculty at Munich University.
Jorge Cortes, M.D.
Jane and John Justin Distinguished Chair in Leukemia Research Section Chief of AML & CML Deputy Chairman, Department of Leukemia The University of Texas MD Anderson Cancer Center Houston, Texas Jorge Cortes, MD, is deputy chair and professor of medicine in the Department of Leukemia at MD Anderson Cancer Center, Houston Texas where he directs the CML and AML Programs. Dr. Cortes received his medical degree in 1986 from the Universidad Nacional Autonoma de Mexico, Mexico City, and has been at MD Anderson Cancer Center since 1991. Dr. Cortes, whose clinical interest focus on new drug development and the management of patients with myelodysplastic syndromes, acute and chronic leukemias, and myeloproliferative disorders has authored over 700 peer-reviewed medical publications in top-tier journals including New England Journal of Medicine, Lancet Oncology, Lancet Hematology, Journal of Clinical Oncology, Leukemia, Blood and many others. He has authored several books and book chapters in prestigious publications such as Cancer Medicine and Harrison’s Principles of Internal Medicine. He has received numerous awards including the Faculty Scholar Award from MD Anderson Cancer Center in 2003, the Annual Celgene Young Investigator Achievement Award for Clinical Research in Hematology in 2005, The Dr. John J. Kenny Award from The Leukemia & Lymphoma Society in 2006, the Service to Mankind Award from The Leukemia & Lymphoma Society in 2007, the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research from MD Anderson Cancer Center in 2007, The Professor David Galton Lecture from the Imperial College of London Hammersmith Hospital in London, UK in 2011, the William Randolph Hearst Foundations Faculty Achievement Award in Education in 2013, and The Gerald P. Bodey Award for Excellence in Education in 2014. He was listed in Listed in “A list of highly influential biomedical researchers, 1996-2011,” Boyack et al. EurJClin Invest, 2013, and named among the Highly Cited Researchers in 2014 by Thomson Reuters in 2014. Dr. Cortes is an Associate Editor for Blood and serves in the Editorial Board of the Journal of Clinical Oncology, Clinical Cancer Research, Leukemia and Lymphoma and the American Journal of Hematology. Dr. Cortes is a member of the Board of Directors of the International CML Foundation and President of the Latin American LeukemiaNet. He led the development of three drugs that were eventually FDA approved for the treatment of CML in 2012. Dr. Cortes is Chair of the Executive Institutional Review Board (IRB) and Chair of the Executive Committee of the Medical Staff at MD Anderson Cancer Center, and program director of the Leukemia Fellowship Program.
John F. DiPersio, M.D., Ph.D.
Dr. DiPersio, Deputy Director, Alvin J. Siteman Cancer Center and Chief of the Division of Oncology at Washington University School of Medicine in St. Louis and the Virginia E. and Samuel J. Golman Professor of Medicine. Dr. DiPersio’s research focuses on fundamental and translational aspects of leukemia and stem cell biology. These studies include identification of genetic abnormalities in human leukemias, understanding processes involving stem cell and leukemia cell trafficking, and clinical and translational programs in both leukemia/myelodysplastic syndrome and stem cell transplantation. Dr. DiPersio is Chair of ASH Scientific Committee on Hematopoiesis, a member of the Board of Scientific Counselors (Clinical Science and Epidemiology) of the National Cancer Institute, and the 2013 recipient of the Daniel P. Schuster Distinguished Translational Investigator Award from Washington University, the 19th Annual AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research in 2014 and the 2014 recipient of the American Society of Hematology Mentor Award for Clinical Investigations.. He has authored or co-authored more than 275 publications and over 60 invited reviews and book chapters. Dr. DiPersio received his M.D. and Ph.D. from the University of Rochester and his B.A. in Biology from Williams College. He completed an internship and residency at Parkland Memorial Hospital and The University of Texas Southwestern Medical Center in Dallas. After serving as chief resident at Parkland Memorial Hospital, Dr. DiPersio completed a fellowship in the Division of Hematology/Oncology at the University of California, Los Angeles (UCLA).
Guillermo Garcia-Manero, M.D.
For the last 15 years, Dr. Garcia-Manero efforts has focused on improving the outcomes and quality of life of patients with leukemia and in particular myelodysplastic syndromes. His work centers around the understanding of the pathophysiology of these disorders in an attempt to develop new therapeutic interventions. He currently lead the largest MDS program in the world and direct the MDS/AML Moon Shot program at MD Anderson. This work has resulted in over 500 publications in the areas of biology, therapy and prognostication of these disorders, and development of multiple therapeutic clinical trials.
Alan F. List, M.D.
Dr. List is the President and Chief Executive Officer of Moffitt Cancer Center in Tampa, FL. Dr. List is internationally recognized for his many contributions in the development of novel, more effective treatment strategies for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which went on to receive fast-track designation from the U.S. Food and Drug Administration and approval for the treatment of patients with MDS and multiple myeloma. This work transformed the natural history of MDS from a premalignant condition that progressed to malignancy requiring aggressive treatment to a condition managed in the outpatient setting with oral agents. Prior to his current position, Dr. List served as Executive Vice President and Physician-in-Chief, the Vice Deputy Physician-in-Chief, and the Chief of the Malignant Hematology Division at Moffitt, where he holds the Morsani Endowed Chair. Before coming to Moffitt in 2003, Dr. List was a Professor of Medicine at the University of Arizona, Tucson, where he also served concurrently as the Director of the Leukemia and Blood and Marrow Transplant Program and Director of the Division of Translational/Clinical Research Program. After earning a medical degree in 1980 from the University of Pennsylvania, Philadelphia, Dr. List completed an internship and residency in internal medicine at the Good Samaritan Medical Center in Phoenix, Arizona. He then completed fellowships in hematology and medical oncology at Vanderbilt University Medical Center in Nashville, Tennessee. Dr. List receives peer-reviewed NIH support for his work and publishes extensively in the areas of MDS and acute leukemia. He lectures nationally and internationally and has received several awards in recognition of his seminal contributions such as induction into The Joshua Lederberg Society; the Emil J. Freireich Award for Clinical Research, M.D. Anderson (2006); the J.P. McCarthy International Prize for Advancing the Body of Scientific Knowledge in Myelodysplastic Syndrome (2004); and the General Motors Cancer Research Foundation Merit Award (1991). He is the author of more than 300 peer-reviewed articles and the Clinician’s Manual on Myelodysplastic Syndromes (2008). He serves as a member of the Myelodysplastic Syndrome Foundation Board of Directors. He also is an active member of the American Society of Clinical Oncology; American Society of Hematology; American Association for Cancer Research; International Society for Experimental Hematology; J.P. McCarthy Foundation Medical Advisory Committee; and the Southwestern Oncology Group.
Gail J. Roboz, M.D.
Dr. Roboz, M.D. is Associate Professor of Medicine and Director of the Clinical and Translational Leukemia Programs at the Weill Medical College of Cornell University and the New York Presbyterian Hospital in New York City. Dr. Roboz graduated summa cum laude from Yale University and received her medical degree from The Mount Sinai School of Medicine in New York, where she was elected to the Alpha Omega Alpha Honor Medical Society and achieved the highest academic standing in the graduating class. She completed Internship in internal medicine at The Beth Israel Hospital in Boston and Residency in internal medicine at the New York Presbyterian Hospital. Dr. Roboz was a Fellow in hematology and medical oncology at Weill Cornell/New York-Presbyterian Hospital and is board-certified in both specialties. She is a member of the American Society of Hematology and the American Society of Clinical Oncology. Her research interests are in developmental therapeutics for acute leukemia, myelodysplastic syndrome, and myeloproliferative disorders. Dr. Roboz is the principal investigator on investigator-initiated and industry-sponsored clinical trials in these areas and has authored or coauthored many manuscripts and abstracts. She sits on the editorial boards of and acts as a reviewer for several journals, and has played an active role as a speaker and panelist at numerous regional, national, and international conferences. Dr. Roboz also serves on the Medical Advisory Board of the Aplastic Anemia and MDS International Foundation.
Mario Sznol, M.D.
Dr. Sznol graduated from Rice University and Baylor College of Medicine (BCM) in Houston, Texas. He trained in internal medicine at BCM and completed a medical oncology fellowship in the Department of Neoplastic Diseases, Mount Sinai Hospital, New York. He spent the next twelve years in the Biologics Evaluation Section (BES), Investigational Drug Branch (IDB), Cancer Therapy Evaluation Program of the National Cancer Institute, and was Head of the BES from 1994-1999. He attended in the Biological Response Modifiers Program, NCI, from 1988-1996 and on the Immunotherapy Service of the Surgery Branch, NCI, from 1997-1999. From 1999-2004, Dr. Sznol was a Vice President and Executive Officer of Vion Pharmaceuticals in New Haven, CT. Dr. Sznol is currently a Professor of Internal Medicine at Yale University School of Medicine. Deputy Chief of the Section of Medical Oncology, Clinical/Translational Research Leader of the Melanoma Program, and co-Director of Yale SPORE in Skin Cancer.
Roland B. Walter, M.D., Ph.D.
Dr. Walter is an Assistant Member, Clinical Research Division, Fred Hutchinson Cancer Research Center, Associate Professor of Medicine, Division of Hematology/Department of Medicine, University of Washington School of Medicine and an Adjunct Associate Professor, Department of Epidemiology, University of Washington School of Public Health. He is also an attending Physician, Division of Hematology/Department of Medicine, University of Washington Medical Center, Seattle, WA and is licensed to practice in the US and Switzerland. Dr. Walter’s holds the following degrees and honors;
Doctor of Medicine (M.D.) Faculty of Medicine, University of Zürich, Switzerland; Doctor of Philosophy (Ph.D.), University of Washington, Seattle, WA; Master of Science Program (Epidemiology – Clinical Research Track), Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA; Master of Science (M.S.), Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA; Clinical/Translational Research Scholar Award, American Society of Hematology, Special Fellow Award, Leukemia & Lymphoma Society, Corresponding Member, Supreme Council, Swiss Academy of Medical Sciences (SAMS), Scholar in Clinical Research Award, Leukemia & Lymphoma Society.